The second-generation ABL TKI dasatinib could yield remarkable responses in the treatment of imatinib-resistant Ph+ B-ALL patients by co-targeting BCR-ABL and SRC family kinases [5, 6]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.